Key facts
- VIDA (Discovery Tools)’s last known valuation is $46.5M (Sep 2023).
- It has raised $44.2M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Next Level Ventures, Blue Heron Capital, OSF Ventures, Mathers Associates, BroadOak Capital Partners — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for VIDA (Discovery Tools)
- ·The full record, as it builds
Funding rounds
No funding rounds for VIDA (Discovery Tools) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VIDA (Discovery Tools)
Operator of an Artificial Intelligence (AI) driven imaging platform designed to enhance data quality and accelerate drug development in life sciences. The company offers clinical trial services, including high-quality imaging, efficient site operations, AI-powered insights, and integrated clinical data, enabling pharmaceutical companies and research organizations to get faster approvals, better biomarker targeting, and improved trial outcomes.
- Sector
- Healthcare
- HQ
- Coralville, IA, United States
- Founded
- 2004
- Employees
- 68
- Website
- vidalung.ai/
- Ownership
- Privately Held (backing)
VIDA (Discovery Tools) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VIDA (Discovery Tools) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VIDA (Discovery Tools) in its N-PORT filings yet. We sweep new filings monthly.